{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T09:05:41Z","timestamp":1782291941305,"version":"3.54.5"},"reference-count":49,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T00:00:00Z","timestamp":1564963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Median overall survival (OS) has improved for patients with newly diagnosed multiple myeloma (NDMM), but prognosis varies depending on baseline patient characteristics. Current models use data from selected clinical trial populations, which prevent application to patients in an unselected community setting that reflects routine clinical practice. Using data from the Connect<jats:sup>\u00ae<\/jats:sup> MM Registry, a large, US, multicentre, prospective observational cohort study (Cohort 1: 2009\u20132011; Cohort 2: 2012\u20132016) of 3011 patients with NDMM, we identified prognostic variables for OS via the multivariable analysis of baseline patient characteristics in Cohort 1 (<jats:italic>n<\/jats:italic>\u00a0=\u00a01493) and developed a tool to examine individual outcomes. Factors associated with OS (<jats:italic>n<\/jats:italic>\u00a0=\u00a01450 treated patients; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b705) were age, del(17p), triplet therapy use, EQ\u20105D mobility, International Staging System stage, solitary plasmacytoma, history of diabetes, platelet count, Eastern Cooperative Oncology Group performance status and serum creatinine, which were used to create survival matrices for 3\u2010 and 5\u2010year OS. The model was internally and externally validated using Connect MM Cohort 2 (Harrell's concordance index, 0\u00b7698), MM\u2010015 (0\u00b7649), and the phase 3 FIRST (0\u00b7647) clinical trials. This novel prognostic tool may help inform outcomes for NDMM in the era of triplet therapy use with novel agents.<\/jats:p>","DOI":"10.1111\/bjh.16139","type":"journal-article","created":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T00:00:03Z","timestamp":1565049603000},"page":"602-614","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Development of a prognostic model for overall survival in multiple myeloma using the Connect<sup>\u00ae<\/sup> MM Patient Registry"],"prefix":"10.1111","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4208-2353","authenticated-orcid":false,"given":"Howard R.","family":"Terebelo","sequence":"first","affiliation":[{"name":"Providence Cancer Institute Southfield MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafat","family":"Abonour","sequence":"additional","affiliation":[{"name":"Indiana University Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina J.","family":"Gasparetto","sequence":"additional","affiliation":[{"name":"Duke University Medical Center Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Toomey","sequence":"additional","affiliation":[{"name":"Steeplechase Cancer Center Somerville NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G. M.","family":"Durie","sequence":"additional","affiliation":[{"name":"Cedars\u2010Sinai Medical Center Los Angeles CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Hardin","sequence":"additional","affiliation":[{"name":"University of South Carolina Columbia SC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[{"name":"Mount Sinai Hospital New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Wagner","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine Winston\u2010Salem NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Narang","sequence":"additional","affiliation":[{"name":"US Oncology Research Columbia MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Dawn","family":"Flick","sequence":"additional","affiliation":[{"name":"Celgene Corporation Summit NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Srinivasan","sequence":"additional","affiliation":[{"name":"Celgene Corporation Summit NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Yue","sequence":"additional","affiliation":[{"name":"Celgene Corporation Summit NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amani","family":"Kitali","sequence":"additional","affiliation":[{"name":"Celgene Corporation Summit NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Celgene Corporation Summit NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-1518","authenticated-orcid":false,"given":"Robert M.","family":"Rifkin","sequence":"additional","affiliation":[{"name":"Rocky Mountain Cancer Centers US Oncology Denver CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the CONNECT MM Registry Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,8,5]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00532.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2010.0114"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402551"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.2307\/2286904"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2014.34.199"},{"key":"e_1_2_7_8_1","first-page":"489","article-title":"Risk stratification in multiple myeloma, part 1: characterization of high\u2010risk disease","volume":"11","author":"Biran N.","year":"2013","journal-title":"Clinical Advances in Hematology & Oncology"},{"key":"e_1_2_7_9_1","first-page":"578","article-title":"Risk stratification in multiple myeloma, part 2: the significance of genetic risk factors in the era of currently available therapies","volume":"11","author":"Biran N.","year":"2013","journal-title":"Clinical Advances in Hematology & Oncology"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/1751-0473-3-17"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/0962280206074463"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022340"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-795047"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.380"},{"key":"e_1_2_7_16_1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2018-99-112093","article-title":"Carfilzomib\u2010Lenalidomide\u2010Dexamethasone (KRd) Induction\u2010Autologous Transplant (ASCT)\u2010Krd consolidation vs KRd 12 cycles vs Carfilzomib\u2010Cyclophosphamide\u2010Dexamethasone (KCd) Induction\u2010ASCT\u2010KCd Consolidation: analysis of the randomized FORTE trial in Newly Diagnosed Multiple Myeloma (NDMM)","volume":"132","author":"Gay F.","year":"2018","journal-title":"Blood"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11121-007-0070-9"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2010.04.001"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4812637"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-726703"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-470-4_2"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110877"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-422683"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.145078"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.291"},{"key":"e_1_2_7_28_1","first-page":"39","article-title":"Temporal trends in survival and healthcare costs in patients with multiple myeloma in the United States","volume":"11","author":"Maiese E.M.","year":"2018","journal-title":"Am Health Drug Benefits"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.6679"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a115101"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112704"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21404"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24402"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.11.007"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.4065\/80.10.1371"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620716680548"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2014.12.002"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8164"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470316696"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"key":"e_1_2_7_43_1","unstructured":"SEER(2019)Cancer Stat Facts: Myeloma. National Cancer Institute. Based on November 2018 SEER data submission posted to the SEER web site April 2019.Bethesda MD https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.013"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-10-7820-0_17"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181c30fb2"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24796"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.3323"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.307"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.16139","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16139","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.16139","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T21:52:28Z","timestamp":1693950748000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.16139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,5]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1111\/bjh.16139"],"URL":"https:\/\/doi.org\/10.1111\/bjh.16139","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,5]]},"assertion":[{"value":"2019-04-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}